Empagliflozin Effective in HFpEF
A double-blind, randomized trial revealed that empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure (HF) in patients with HF and a preserved ejection fraction (HFpEF), regardless of the presence or absence of diabetes. The trial included 5988 patients (average 72 years, about 45% women, and […]